<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>EXEMESTANE- exemestaneÂ tabletÂ </strong><br>Alvogen Inc. <br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<span class="Bold">These highlights do not include all the information needed to use</span><span class="Bold">exemestane safely and effectively. See full prescribing information for exemestane.<br><br><span class="Bold">Exemestane tablets, oral<br></span><span class="Bold">Initial U.S. Approval: 1999</span><br></span>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta">Dosage and Administration, Dose Modifications (<a href="#_f71b4a9f-934a-ac7a-3b93-41c935a5133b">2.2</a>)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  05/2014<br><span class="Bold"></span>Warnings and Precautions, Reductions in BMD (<a href="#_19b7c9b9-d18f-abe2-6b58-27a3c4991fdf">5.3</a>) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  05/2014 </p></div>
</div>
<div><div></div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">Exemestane is an aromatase inhibitor indicated for:<br>â€¢ <span class="Bold"></span><span class="Bold"></span>adjuvant treatment of postmenopausal women with estrogen receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to exemestane for completion of a total of five consecutive years of adjuvant hormonal therapy (<a href="#_b4e768f6-f8d9-0a87-4c73-00301a07c199">14.1</a>).<br>â€¢ the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy (<a href="#_5c4255fa-9914-aff3-b48c-ca771445b823">14.2</a>). </p></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><p class="Highlighta">One 25 mg tablet once daily after a meal (<a href="#_0d2c7b98-c8c7-204d-a8e4-e80e60d6b0ef">2.1</a>). </p></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets: 25 mg (<a href="#DOSAGE_FORMS_AND_STRENGTHS">3</a>). </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">â€¢Patients with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the drug or to any of the excipients (<a href="#_2e974acc-3e93-4bd4-f178-2dbd47e10af8">4.1</a>).<br>â€¢Women of premenopausal endocrine status, including pregnant women (<a href="#_01f038c1-110f-5f28-dc7a-acc1cf6868f3">4.2</a>). </p></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><p class="Highlighta">â€¢Reductions in bone mineral density (BMD) over time are seen withÂ exemestane use (<a href="#_19b7c9b9-d18f-abe2-6b58-27a3c4991fdf">5.3</a>).<br>â€¢Routine assessment of 25-hydroxy vitamin D levels prior to the start of aromatase inhibitor treatment should be performed (<a href="#_900e46bc-9820-b9c2-83c1-5acf37961fb2">5.4</a>) </p></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">â€¢ Early breast cancer: Adverse events occurring in â‰¥10% of patients in any treatment group (exemestane vs. tamoxifen) were <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span> (21.2% vs. 19.9%), <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (16.1% vs. 14.7%), <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span> (14.6% vs. 8.6%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (13.1% vs. 10.8%), <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> (12.4% vs. 8.9%), and increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> (11.8% vs. 10.4%). Discontinuation rates due to AEs were similar between exemestane and tamoxifen (6.3% vs. 5.1%). Incidences of cardiac ischemic events (<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, angina, and <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span>) were exemestane 1.6%, tamoxifen 0.6%. Incidence of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>: exemestane 0.4%, tamoxifen 0.3% (<a href="#ADVERSE_REACTIONS">6</a>, <a href="#_30cea6e2-ece3-d9de-eb04-c7f4640b46bc">6.1</a>).<br><span class="Bold">â€¢ </span>Advanced breast cancer: Most common adverse events were mild to moderate and included <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span> (13% vs. 5%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (9% vs. 5%), <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (8% vs. 10%), increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> (4% vs. 8%), and <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span> (3% vs. 6%) for exemestane and megestrol acetate, respectively (<a href="#ADVERSE_REACTIONS">6</a>, <a href="#_30cea6e2-ece3-d9de-eb04-c7f4640b46bc">6.1</a>). </p>
<p class="Highlighta"> </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Alvogen at 1-866-770-3024 or FDA at 1-800-FDA-1088 or </span><span class="Bold Italics">www.fda.gov/medwatch</span>.<span class="Bold"></span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><p class="Highlighta">â€¢Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. Increase the exemestane dose to 50 mg (<a href="#_f71b4a9f-934a-ac7a-3b93-41c935a5133b">2.2</a>, <a href="#DRUG_INTERACTIONS">7</a>).  </p></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 7/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc"><span class="Bold">1.1 Adjuvant Treatment of Postmenopausal Women</span></a></h2>
<h2><a href="#section-1.2" class="toc"><span class="Bold">1.2 Advanced Breast Cancer in Postmenopausal Women</span></a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc"><span class="Bold">2.1 Recommended Dose</span></a></h2>
<h2><a href="#section-2.2" class="toc"><span class="Bold">2.2 Dose Modifications</span></a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc"><span class="Bold">4.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></span></a></h2>
<h2><a href="#section-4.2" class="toc"><span class="Bold">4.2 Pregnancy</span></a></h2>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc"><span class="Bold">5.1 Administration with Estrogen-Containing Agents</span></a></h2>
<h2><a href="#section-5.2" class="toc"><span class="Bold">5.2 Laboratory Tests</span></a></h2>
<h2><a href="#section-5.3" class="toc"><span class="Bold">5.3 Reductions in Bone Mineral Density (BMD)</span></a></h2>
<h2><a href="#section-5.4" class="toc"><span class="Bold">5.4 Vitamin D Assessment</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc"><span class="Bold">6.1 Clinical Trial Experience</span></a></h2>
<h2><a href="#section-6.2" class="toc"><span class="Bold">6.2 Post-Marketing Experience</span></a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc"><span class="Bold">8.6 Hepatic </span><span class="Bold">Impairment</span><span class="Bold"></span></a></h2>
<h2><a href="#section-8.5" class="toc"><span class="Bold">8.7 Renal </span><span class="Bold">Impairment</span><span class="Bold"></span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment Of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc"><span class="Bold">14.1 Adjuvant Treatment in Early Breast Cancer</span></a></h2>
<h2><a href="#section-13.2" class="toc"><span class="Bold">1</span><span class="Bold">4.2 Treatment of Advanced Breast Cancer</span></a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc"><span class="Bold">17.1 Premenopausal Women</span></a></h2>
<h2><a href="#section-15.2" class="toc"><span class="Bold">1</span><span class="Bold">7.2 Other Estrogen-Containing Agents</span></a></h2>
<h2><a href="#section-15.3" class="toc"><span class="Bold">17.3 Bone Effects</span></a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.1"></a><p></p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="INDICATIONS_AND_USAGE"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="42229-5">
<a name="_f8f0a148-0835-5195-5d44-30ea03f98253"></a><a name="section-1.1"></a><p></p>
<h2><span class="Bold">1.1 Adjuvant Treatment of Postmenopausal Women</span></h2>
<p class="First">Exemestane is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to exemestane for completion of a total of five consecutive years of adjuvant hormonal therapy <span class="Italics">[see Clinical Studies (</span><a href="#_b4e768f6-f8d9-0a87-4c73-00301a07c199">14.1</a><span class="Italics">)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_ef6b2e1f-b92b-7c6e-ecdd-3d24e320098f"></a><a name="section-1.2"></a><p></p>
<h2><span class="Bold">1.2 Advanced Breast Cancer in Postmenopausal Women</span></h2>
<p class="First">Exemestane is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy <span class="Italics">[see Clinical Studies (</span><a href="#_5c4255fa-9914-aff3-b48c-ca771445b823">14.2</a><span class="Italics">)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="DOSAGE_AND_ADMINISTRATION"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="42229-5">
<a name="_0d2c7b98-c8c7-204d-a8e4-e80e60d6b0ef"></a><a name="section-2.1"></a><p></p>
<h2><span class="Bold">2.1 Recommended Dose</span></h2>
<p class="First">The recommended dose of exemestane in early and advanced breast cancer is one 25 mg tablet to be taken once daily after a meal.<br><span class="Bold">â€¢ </span>adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to exemestane for completion of a total of five consecutive years of adjuvant hormonal therapy.<br><span class="Bold">â€¢ </span>the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_f71b4a9f-934a-ac7a-3b93-41c935a5133b"></a><a name="section-2.2"></a><p></p>
<h2><span class="Bold">2.2 Dose Modifications</span></h2>
<p class="First">Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. For patients receiving exemestane with a strong CYP 3A4 inducer such as rifampicin or phenytoin, the recommended dose of exemestane is 50 mg once daily after a meal [<span class="Italics">see Drug Interactions</span><span class="Italics">(</span><a href="#DRUG_INTERACTIONS">7</a><span class="Italics">)</span><span class="Italics">and Clinical Pharmacology</span><span class="Italics">(</span><a href="#PHARMACOKINETICS">12.3</a><span class="Italics">)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="DOSAGE_FORMS_AND_STRENGTHS"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Exemestane tablets are white to off-white, round compound cup tablet with â€œ25â€? on one side and plain on the reverse.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="CONTRAINDICATIONS"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="42229-5">
<a name="_2e974acc-3e93-4bd4-f178-2dbd47e10af8"></a><a name="section-4.1"></a><p></p>
<h2><span class="Bold">4.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></span></h2>
<p class="First">Exemestane Tablets are contraindicated in patients with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the drug or to any of the excipients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_01f038c1-110f-5f28-dc7a-acc1cf6868f3"></a><a name="section-4.2"></a><p></p>
<h2><span class="Bold">4.2 Pregnancy</span></h2>
<p class="First">Exemestane may cause fetal harm when administered to a pregnant woman. Based on its mechanism of action exemestane is expected to result in adverse reproductive effects. In non-clinical studies in rats and rabbits, exemestane was embryotoxic, fetotoxic, and abortifacient.<br></p>
<p>Exemestane is contraindicated in women who are or may become pregnant. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.<br></p>
<p>Exemestane Tablets should not be administered to premenopausal women <span class="Italics">[</span><span class="Italics">see Use in Specific Populations</span><span class="Italics">(</span><a href="#PREGNANCY">8.1</a><span class="Italics">)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="WARNINGS_AND_PRECAUTIONS"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="42229-5">
<a name="_756c07f5-a05d-a501-fd97-85e51967c44a"></a><a name="section-5.1"></a><p></p>
<h2><span class="Bold">5.1 Administration with Estrogen-Containing Agents</span></h2>
<p class="First">Exemestane should not be coadministered with estrogen-containing agents as these could interfere with its pharmacologic action.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_845c91df-5422-9ace-babd-efa199f4343b"></a><a name="section-5.2"></a><p></p>
<h2><span class="Bold">5.2 Laboratory Tests</span></h2>
<p class="First">In patients with early breast cancer, the incidence of hematological abnormalities of Common Toxicity Criteria (CTC) grade â‰¥1 was lower in the exemestane treatment group, compared with tamoxifen. Incidence of CTC grade 3 or 4 abnormalities was low (approximately 0.1%) in both treatment groups. Approximately 20% of patients receiving exemestane in clinical studies in advanced breast cancer experienced CTC grade 3 or 4 <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphocytopenia</span>. Of these patients, 89% had a pre-existing lower grade <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphopenia</span>. Forty percent of patients either recovered or improved to a lesser severity while on treatment. Patients did not have a significant increase in <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span>, and no <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> were observed. Elevations of serum levels of AST, ALT, alkaline phosphatase, and gamma glutamyl transferase &gt;5 times the upper value of the normal range (i.e., â‰¥ CTC grade 3) have been rarely reported in patients treated for advanced breast cancer but appear mostly attributable to the underlying presence of liver and/or bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>. In the comparative study in advanced breast cancer patients, CTC grade 3 or 4 elevation of gamma glutamyl transferase without documented evidence of liver <span class="product-label-link" type="condition" conceptid="4147162" conceptname="Secondary malignant neoplasm of respiratory and digestive systems">metastasis</span> was reported in 2.7% of patients treated with exemestane and in 1.8% of patients treated with megestrol acetate.</p>
<p>In patients with early breast cancer, elevations in bilirubin, alkaline phosphatase, and creatinine were more common in those receiving exemestane than either tamoxifen or placebo. Treatment-emergent bilirubin elevations (any CTC grade) occurred in 5.3% of exemestane patients and 0.8% of tamoxifen patients on the Intergroup Exemestane Study (IES), and in 6.9% of exemestane treated patients vs. 0% of placebo treated patients in the 027 study. CTC grade 3â€“4 increases in bilirubin occurred in 0.9% of exemestane treated patients compared to 0.1% of tamoxifen treated patients. Alkaline phosphatase elevations of any CTC grade occurred in 15.0% of exemestane treated patients on the IES compared to 2.6% of tamoxifen treated patients, and in 13.7% of exemestane treated patients compared to 6.9% of placebo treated patients in study 027. Creatinine elevations occurred in 5.8% of exemestane treated patients and 4.3% of tamoxifen treated patients on the IES and in 5.5% of exemestane treated patients and 0% of placebo treated patients in study 027.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_19b7c9b9-d18f-abe2-6b58-27a3c4991fdf"></a><a name="section-5.3"></a><p></p>
<h2><span class="Bold">5.3 Reductions in Bone Mineral Density (BMD)</span></h2>
<p class="First">Reductions in bone mineral density (BMD) over time are seen with exemestane use. Table 1 describes changes in BMD from baseline to 24 months in patients receiving exemestane compared to patients receiving tamoxifen (IES) or placebo (027). Concomitant use of bisphosphonates, vitamin D supplementation, and calcium was not allowed.</p>
<p><img alt="table-1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=61d86c55-9946-273f-4f22-42d3fc33d143&amp;name=table-1.jpg"></p>
<p>During adjuvant treatment with exemestane, women with <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> or at risk of <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> should have their bone mineral density formally assessed by bone densitometry at the commencement of treatment. Monitor patients for bone mineral density loss and treat as appropriate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_900e46bc-9820-b9c2-83c1-5acf37961fb2"></a><a name="section-5.4"></a><p></p>
<h2><span class="Bold">5.4 Vitamin D Assessment</span></h2>
<p class="First">Routine assessment of 25-hydroxy vitamin D levels prior to the start of aromatase inhibitor treatment should be performed, due to the high prevalence of <span class="product-label-link" type="condition" conceptid="436070" conceptname="Vitamin D deficiency">vitamin D deficiency</span> in women with early breast cancer (EBC). Women with <span class="product-label-link" type="condition" conceptid="436070" conceptname="Vitamin D deficiency">vitamin D deficiency</span> should receive supplementation with vitamin D.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ADVERSE_REACTIONS"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">Exemestane was generally well tolerated and adverse events were usually mild to moderate. In the adjuvant treatment of early breast cancer, adverse events occurring in â‰¥10% of patients in any treatment group (exemestane vs. tamoxifen) were <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span> (21.2% vs. 19.9%), <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (16.1% vs. 14.7%), <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span> (14.6% vs. 8.6%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (13.1% vs. 10.8%), <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> (12.4% vs. 8.9%), and increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> (11.8% vs. 10.4%). Discontinuation rates due to AEs were similar between exemestane and tamoxifen (6.3% vs. 5.1%). Incidences of cardiac ischemic events (<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, angina, and <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span>) were exemestane 1.6%, tamoxifen 0.6%. Incidence of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>: exemestane 0.4%, tamoxifen 0.3%.</p>
<p>In the treatment of advanced breast cancer, the most common adverse events were mild to moderate and included <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span> (13% vs. 5%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (9% vs. 5%), <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (8% vs. 10%), increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> (4% vs. 8%), and <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span> (3% vs. 6%) for exemestane and megestrol acetate, respectively.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="_30cea6e2-ece3-d9de-eb04-c7f4640b46bc"></a><a name="section-6.1"></a><p></p>
<h2><span class="Bold">6.1 Clinical Trial Experience</span></h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.Â </p>
<p><span class="Bold">Adjuvant Therapy</span><br>The data described below reflect exposure to exemestane in 2325 postmenopausal women with early breast cancer. Exemestane tolerability in postmenopausal women with early breast cancer was evaluated in two well-controlled trials: the IES study (<a href="#_b4e768f6-f8d9-0a87-4c73-00301a07c199">14.1</a>) and the 027 study (a randomized, placebo-controlled, double-blind, parallel group study specifically designed to assess the effects of exemestane on bone metabolism, hormones, lipids, and coagulation factors over 2 years of treatment).<br>The median duration of adjuvant treatment was 27.4 months and 27.3 months for patients receiving exemestane or tamoxifen, respectively, within the IES study and 23.9 months for patients receiving exemestane or placebo within the 027 study. Median duration of observation after randomization for exemestane was 34.5 months and for tamoxifen was 34.6 months. Median duration of observation was 30 months for both groups in the 027 study.</p>
<p>Certain adverse events, which were expected based on the known pharmacological properties and side effect profiles of test drugs, were actively sought through a positive checklist. Signs and symptoms were graded for severity using CTC in both studies. Within the IES study, the presence of some illnesses/conditions was monitored through a positive checklist without assessment of severity. These included <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, other <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">cardiovascular disorders</span>, gynecological disorders, <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>, <span class="product-label-link" type="condition" conceptid="4188189" conceptname="Osteoporotic fracture">osteoporotic fractures</span>, other primary cancer, and hospitalizations.Â </p>
<p>Exemestane was generally well tolerated and adverse events were usually mild to moderate. Within the IES study, discontinuations due to adverse events occurred in 6.3% and 5.1% of patients receiving exemestane and tamoxifen, respectively, and in 12.3% and 4.1% of patients receiving exemestane or placebo respectively within study 027.</p>
<p><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> due to any cause were reported for 1.3% of the exemestane treated patients and 1.4% of the tamoxifen treated patients within the IES study. There were 6 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> due to <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> on the exemestane arm compared to 2 on tamoxifen. There were 5 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> due to <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> on the exemestane arm compared to 2 on tamoxifen.</p>
<p>The incidence of cardiac ischemic events (<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, angina, and <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span>) was 1.6% in exemestane treated patients and 0.6% in tamoxifen treated patients in the IES study. <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac failure</span> was observed in 0.4% of exemestane treated patients and 0.3% of tamoxifen treated patients.</p>
<p>Treatment-emergent adverse events and illnesses including all causalities and occurring with an incidence of â‰¥5% in either treatment group of the IES study during or within one month of the end of treatment are shown in Table 2.</p>
<p><img alt="table-2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=61d86c55-9946-273f-4f22-42d3fc33d143&amp;name=exemestane-table-2.jpg"></p>
<p>In the IES study, as compared to tamoxifen, exemestane was associated with a higher incidence of events in <span class="product-label-link" type="condition" conceptid="4244662" conceptname="Disorder of musculoskeletal system">musculoskeletal disorders</span> and in <span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">nervous system disorders</span>, including the following events occurring with frequency lower than 5% (<span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> [4.6% vs. 2.8%], <span class="product-label-link" type="condition" conceptid="433565" conceptname="Juvenile osteochondrosis of spine">osteochondrosis</span> and <span class="product-label-link" type="condition" conceptid="77965" conceptname="Acquired trigger finger">trigger finger</span> [0.3% vs. 0 for both events], <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span> [2.6% vs. 0.9%], <span class="product-label-link" type="condition" conceptid="380094" conceptname="Carpal tunnel syndrome">carpal tunnel syndrome</span> [2.4% vs. 0.2%], and <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> [0.6% vs. 0.1%]). <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> was also more frequent in the exemestane group (4.2% vs. 2.2%). Clinical <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> were reported in 94 patients receiving exemestane (4.2%) and 71 patients receiving tamoxifen (3.1%). After a median duration of therapy of about 30 months and a median follow-up of about 52 months, <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcer</span> was observed at a slightly higher frequency in the exemestane group compared to tamoxifen (0.7% vs. &lt;0.1%). The majority of patients on exemestane with <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcer</span> received concomitant treatment with non-steroidal anti-inflammatory agents and/or had a prior history.Â </p>
<p>Tamoxifen was associated with a higher incidence of <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span> [3.1% vs. 1.5%], <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span> [2.0% vs. 0.9%], <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span> [1.7% vs. 0.6%], and uterine <span class="product-label-link" type="condition" conceptid="4187628" conceptname="Polyp">polyps</span> [2.4% vs. 0.4%].<br>Common adverse events occurring in study 027 are described in Table 3.</p>
<p><img alt="table-3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=61d86c55-9946-273f-4f22-42d3fc33d143&amp;name=table-3.jpg"></p>
<p><span class="Bold">Treatment of Advanced Breast Cancer<br></span>A total of 1058 patients were treated with exemestane 25 mg once daily in the clinical trials program. Only one <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was considered possibly related to treatment with exemestane; an 80-year-old woman with known <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> had a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> with <span class="product-label-link" type="condition" conceptid="4212484" conceptname="Multiple organ failure">multiple organ failure</span> after 9 weeks on study treatment. In the clinical trials program, only 3% of the patients discontinued treatment with exemestane because of adverse events, mainly within the first 10 weeks of treatment; late discontinuations because of adverse events were uncommon (0.3%).</p>
<p>In the comparative study, adverse reactions were assessed for 358 patients treated with exemestane and 400 patients treated with megestrol acetate. Fewer patients receiving exemestane discontinued treatment because of adverse events than those treated with megestrol acetate (2% vs. 5%). Adverse events that were considered drug related or of indeterminate cause included <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span> (13% vs. 5%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (9% vs. 5%), <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (8% vs. 10%), increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> (4% vs. 8%), and <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span> (3% vs. 6%) for exemestane and megestrol acetate, respectively. The proportion of patients experiencing an excessive <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> (&gt;10% of their baseline weight) was significantly higher with megestrol acetate than with exemestane (17% vs. 8%). Table 4 shows the adverse events of all CTC grades, regardless of causality, reported in 5% or greater of patients in the study treated either with exemestane or megestrol acetate.</p>
<p><img alt="table-4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=61d86c55-9946-273f-4f22-42d3fc33d143&amp;name=table-4.jpg"><br>Less frequent adverse events of any cause (from 2% to 5%) reported in the comparative study for patients receiving exemestane 25 mg once daily were <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, generalized <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="73571" conceptname="Pathological fracture">pathological fracture</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, and <span class="product-label-link" type="condition" conceptid="435839" conceptname="Lymphedema">lymphedema</span>.</p>
<p>Additional adverse events of any cause observed in the overall clinical trials program (N = 1058) in 5% or greater of patients treated with exemestane 25 mg once daily but not in the comparative study included <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> at tumor sites (8%), <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span> (6%), and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (5%). Adverse events of any cause reported in 2% to 5% of all patients treated with exemestane 25 mg in the overall clinical trials program but not in the comparative study included <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">skeletal pain</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, and <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>.<br></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_4e602da4-aa6d-141f-24fe-c33033818e4d"></a><a name="section-6.2"></a><p></p>
<h2><span class="Bold">6.2 Post-Marketing Experience</span></h2>
<p class="First">The following adverse reactions have been identified during post approval use of exemestane. Because reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune system disorders</span></span>-<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span></p>
<p><span class="Italics">Hepatobiliary disorders</span>-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> including <span class="product-label-link" type="condition" conceptid="4318541" conceptname="Cholestatic hepatitis">cholestatic hepatitis</span> </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span>-<span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span> </p>
<p><span class="Italics">Skin and subcutaneous tissue disorders</span>-<span class="product-label-link" type="condition" conceptid="45773387" conceptname="Acute generalized exanthematous pustulosis">acute generalized exanthematous pustulosis</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, pruritusÂ  </p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="DRUG_INTERACTIONS"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. Johnâ€™s wort) may significantly decrease exposure to exemestane. Dose modification is recommended for patients who are also receiving a strong CYP 3A4 inducer <span class="Italics">[</span><span class="Italics">see Dosage and Administration</span><span class="Italics">(</span><a href="#_f71b4a9f-934a-ac7a-3b93-41c935a5133b">2.2</a><span class="Italics">)</span><span class="Italics">and Clinical Pharmacology</span><span class="Italics">(</span><a href="#PHARMACOKINETICS">12.3</a><span class="Italics">)]</span>.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="USE_IN_SPECIFIC_POPULATIONS"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="42228-7">
<a name="PREGNANCY"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category X. See â€œContraindicationsâ€? section.<br>Exemestane can cause fetal harm when administered to a pregnant woman and the clinical benefit to premenopausal women with breast cancer has not been demonstrated. Exemestane is contraindicated in women who are or may become pregnant. There are no adequate and well-controlled studies of exemestane in pregnant women.</p>
<p>In non-clinical studies in rats and rabbits, exemestane was embryotoxic, fetotoxic, and abortifacient. Radioactivity related to<span class="Sup">14</span>C-exemestane crossed the placenta of rats following oral administration of 1 mg/kg exemestane. The concentration of exemestane and its metabolites was approximately equivalent in maternal and fetal blood. When rats were administered exemestane from 14 days prior to mating until either days 15 or 20 of gestation, and resuming for the 21 days of lactation, an increase in placental weight was seen at 4 mg/kg/day (approximately 1.5 times the recommended human daily dose on a mg/m<span class="Sup">2</span> basis). Prolonged gestation and abnormal or difficult labor was observed at doses equal to or greater than 20 mg/kg/day. Increased resorption, reduced number of live fetuses, decreased fetal weight, and retarded ossification were also observed at these doses. No malformations were noted when exemestane was administered to pregnant rats during the organogenesis period at doses up to 810 mg/kg/day (approximately 320 times the recommended human dose on a mg/m<span class="Sup">2</span> basis). Daily doses of exemestane, given to rabbits during organogenesis, caused a decrease in placental weight at 90 mg/kg/day (approximately 70 times the recommended human daily dose on a mg/m<span class="Sup">2</span> basis). Abortions, an increase in resorptions, and a reduction in fetal body weight were seen at 270 mg/kg/day. There was no increase in the incidence of malformations in rabbits at doses up to 270 mg/kg/day (approximately 210 times the recommended human dose on a mg/m<span class="Sup">2</span> basis).</p>
<p>If this drug is used during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus and the potential risk for pregnancy loss.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="NURSING_MOTHERS"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Exemestane is only indicated in postmenopausal women. However, radioactivity related to exemestane appeared in rat milk within 15 minutes of oral administration of radiolabeled exemestane. Concentrations of exemestane and its metabolites were approximately equivalent in the milk and plasma of rats for 24 hours after a single oral dose of 1 mg/kg <span class="Sup">14</span>C-exemestane. It is not known whether exemestane is excreted in human milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse reaction in nursing infants from exemestane, a decision should be made whether to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="PEDIATRIC_USE"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="GERIATRIC_USE"></a><a name="section-8.4"></a><p></p>
<h2>
<span class="Bold">8.6 Hepatic </span><span class="Bold">Impairment</span><span class="Bold"></span>
</h2>
<p class="First">The AUC of exemestane was increased in subjects with moderate or severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Childs-Pugh B or C) <span class="Italics">[</span><span class="Italics">see Clinical Pharmacology</span><span class="Italics">(</span><a href="#PHARMACOKINETICS">12.3</a><span class="Italics">)]</span>. However, based on experience with exemestane at repeated doses up to 200 mg daily that demonstrated a moderate increase in non life-threatening adverse events, dosage adjustment does not appear to be necessary. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_5e5cd595-a333-a749-43c0-01fa9a1b14b2"></a><a name="section-8.5"></a><p></p>
<h2>
<span class="Bold">8.7 Renal </span><span class="Bold">Impairment</span><span class="Bold"></span>
</h2>
<p class="First">The AUC of exemestane was increased in subjects with moderate or severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance &lt;35 mL/min/1.73 m<span class="Sup">2</span>)<span class="Italics"> [see Clinical Pharmacology</span><span class="Italics">(</span><a href="#PHARMACOKINETICS">12.3</a><span class="Italics">)</span><span class="Italics">]</span>. However, based on experience with exemestane at repeated doses up to 200 mg daily that demonstrated a moderate increase in non life-threatening adverse events, dosage adjustment does not appear to be necessary.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="OVERDOSAGE"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Clinical trials have been conducted with exemestane given as a single dose to healthy female volunteers at doses as high as 800 mg and daily for 12 weeks to postmenopausal women with advanced breast cancer at doses as high as 600 mg. These dosages were well tolerated. There is no specific antidote to overdosage and treatment must be symptomatic. General supportive care, including frequent monitoring of vital signs and close observation of the patient, is indicated.Â </p>
<p>A male child (age unknown) accidentally ingested a 25-mg tablet of exemestane. The initial physical examination was normal, but blood tests performed 1 hour after ingestion indicated leucocytosis (WBC 25000/mm<span class="Sup">3</span> with 90% <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span>). Blood tests were repeated 4 days after the incident and were normal. No treatment was given.</p>
<p>In mice, mortality was observed after a single oral dose of exemestane of 3200 mg/kg, the lowest dose tested (about 640 times the recommended human dose on a mg/m<span class="Sup">2</span> basis). In rats and dogs, mortality was observed after single oral doses of exemestane of 5000 mg/kg (about 2000 times the recommended human dose on a mg/m<span class="Sup">2</span> basis) and of 3000 mg/kg (about 4000 times the recommended human dose on a mg/m<span class="Sup">2</span> basis), respectively.Â </p>
<p><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> were observed after single doses of exemestane of 400 mg/kg and 3000 mg/kg in mice and dogs (approximately 80 and 4000 times the recommended human dose on a mg/m<span class="Sup">2</span> basis), respectively.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="DESCRIPTION"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Exemestane Tablets for oral administration contain 25 mg of exemestane, an irreversible, steroidal aromatase inactivator. Exemestane is chemically described as 6-methylenandrosta-1,4-diene-3,17-dione. Its molecular formula is C<span class="Sub">20</span>H<span class="Sub">24</span>O<span class="Sub">2</span> and its structural formula is as follows:</p>
<p><img alt="structure " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=61d86c55-9946-273f-4f22-42d3fc33d143&amp;name=structure.jpg"></p>
<p>The active ingredient is a white to slightly yellow powder with a molecular weight of 296.41. Exemestane is freely soluble in tetrahydrofuran and dimethylformamide; soluble in acetone, acetonitrile, methanol, and ethyl acetate; sparingly soluble in ethanol; very slightly soluble in nhexane and insoluble in water.</p>
<p>Each Exemestane Tablet contains the following inactive ingredients: mannitol, copovidone, crospovidone, silicified microcrystalline cellulose, sodium starch glycolate, magnesium stearate, titanium dioxide, polyethylene glycol 400, and hypromellose.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="CLINICAL_PHARMACOLOGY"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="43679-0">
<a name="MECHANISM_OF_ACTION"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Breast cancer cell growth may be estrogen-dependent. Aromatase is the principal enzyme that converts <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> to estrogens both in pre- and postmenopausal women. While the main source of estrogen (primarily estradiol) is the ovary in premenopausal women, the principal source of circulating estrogens in postmenopausal women is from conversion of adrenal and ovarian <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> (androstenedione and testosterone) to estrogens (estrone and estradiol) by the aromatase enzyme in peripheral tissues. Estrogen deprivation through aromatase inhibition is an effective and selective treatment for some postmenopausal patients with hormone-dependent breast cancer. </p>
<p>Exemestane is an irreversible, steroidal aromatase inactivator, structurally related to the natural substrate androstenedione. It acts as a false substrate for the aromatase enzyme, and is processed to an intermediate that binds irreversibly to the active site of the enzyme, causing its inactivation, an effect also known as â€œsuicide inhibition.â€? Exemestane significantly lowers circulating estrogen concentrations in postmenopausal women, but has no detectable effect on adrenal biosynthesis of corticosteroids or aldosterone. Exemestane has no effect on other enzymes involved in the steroidogenic pathway up to a concentration at least 600 times higher than that inhibiting the aromatase enzyme.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="PHARMACODYNAMICS"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First"><span class="Italics">Effect on Estrogens:</span> Multiple doses of exemestane ranging from 0.5 to 600 mg/day were administered to postmenopausal women with advanced breast cancer. Plasma estrogen (estradiol, estrone, and estrone sulfate) suppression was seen starting at a 5-mg daily dose of exemestane, with a maximum suppression of at least 85% to 95% achieved at a 25-mg dose. Exemestane 25 mg daily reduced whole body aromatization (as measured by injecting radiolabeled androstenedione) by 98% in postmenopausal women with breast cancer. After a single dose of exemestane 25 mg, the maximal suppression of circulating estrogens occurred 2 to 3 days after dosing and persisted for 4 to 5 days.</p>
<p><span class="Italics">Effect on Corticosteroids:</span> In multiple-dose trials of doses up to 200 mg daily, exemestane selectivity was assessed by examining its effect on adrenal steroids. Exemestane did not affect cortisol or aldosterone secretion at baseline or in response to ACTH at any dose. Thus, no glucocorticoid or mineralocorticoid replacement therapy is necessary with exemestane treatment.</p>
<p><span class="Italics">Other Endocrine Effects:</span> Exemestane does not bind significantly to steroidal receptors, except for a slight affinity for the androgen receptor (0.28% relative to dihydrotestosterone). The binding affinity of its 17-dihydrometabolite for the androgen receptor, however, is 100 times that of the parent compound. Daily doses of exemestane up to 25 mg had no significant effect on circulating levels of androstenedione, dehydroepiandrosterone sulfate, or 17- hydroxyprogesterone, and were associated with small decreases in circulating levels of testosterone. Increases in testosterone and androstenedione levels have been observed at daily doses of 200 mg or more. A dose-dependent decrease in <span class="product-label-link" type="condition" conceptid="4206320" conceptname="Sex steroid binding globulin">sex hormone binding globulin</span> (SHBG) has been observed with daily exemestane doses of 2.5 mg or higher. Slight, nondose-dependent increases in serum luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels have been observed even at low doses as a consequence of feedback at the pituitary level. Exemestane 25 mg daily had no significant effect on thyroid function [free triiodothyronine (FT3), free thyroxine (FT4), and thyroid stimulating hormone (TSH)].</p>
<p><span class="Italics">Coagulation and Lipid Effects:</span> In study 027 of postmenopausal women with early breast cancer treated with exemestane (N=73) or placebo (N=73), there was no change in the coagulation parameters <span class="product-label-link" type="condition" conceptid="44809202" conceptname="Activated partial thromboplastin time">activated partial thromboplastin time</span> [APTT], <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time [PT], and fibrinogen. Plasma HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> was decreased 6â€“9% in exemestane treated patients; total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, triglycerides, <span class="product-label-link" type="condition" conceptid="4122128" conceptname="Apolipoprotein">apolipoprotein</span>-A1, <span class="product-label-link" type="condition" conceptid="4122128" conceptname="Apolipoprotein">apolipoprotein</span>-B, and lipoprotein-a were unchanged. An 18% increase in homocysteine levels was also observed in exemestane treated patients compared with a 12% increase seen with placebo.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="PHARMACOKINETICS"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Following oral administration to healthy postmenopausal women, plasma concentrations of exemestane decline polyexponentially with a mean terminal half-life of about 24 hours. The pharmacokinetics of exemestane are dose proportional after single (10 to 200 mg) or repeated oral doses (0.5 to 50 mg). Following repeated daily doses of exemestane 25 mg, plasma concentrations of unchanged drug are similar to levels measured after a single dose. Pharmacokinetic parameters in postmenopausal women with advanced breast cancer following single or repeated doses have been compared with those in healthy, postmenopausal women. After repeated dosing, the average oral clearance in women with advanced breast cancer was 45% lower than the oral clearance in healthy postmenopausal women, with corresponding higher systemic exposure. Mean AUC values following repeated doses in women with breast cancer (75.4 ngâˆ™h/mL) were about twice those in healthy women (41.4 ngâˆ™h/mL).</p>
<p><span class="Italics">Absorption:</span> Following oral administration, exemestane appeared to be absorbed more rapidly in women with breast cancer than in the healthy women, with a mean -t<span class="Sub">max</span> of 1.2 hours in the women with breast cancer and 2.9 hours in healthy women. Approximately 42% of radiolabeled exemestane was absorbed from the gastrointestinal tract. A high-fat breakfast increased AUC and C<span class="Sub">max</span> of exemestane by 59% and 39%, respectively, compared to fasted state.</p>
<p><span class="Italics">Distribution:</span> Exemestane is distributed extensively into tissues. Exemestane is 90% bound to plasma proteins and the fraction bound is independent of the total concentration. Albumin and Î±<span class="Sub">1</span>1- acid glycoprotein both contribute to the binding. The distribution of exemestane and its metabolites into blood cells is negligible.</p>
<p><span class="Italics">Metabolism:</span> Exemestane is extensively metabolized, with levels of the unchanged drug in plasma accounting for less than 10% of the total radioactivity. The initial steps in the metabolism of exemestane are oxidation of the methylene group in position 6 and reduction of the 17-keto group with subsequent formation of many secondary metabolites. Each metabolite accounts only for a limited amount of drug-related material. The metabolites are inactive or inhibit aromatase with decreased potency compared with the parent drug. One metabolite may have androgenic activity <span class="Italics">[see Clinical Pharmacology </span><span class="Italics">(</span><a href="#PHARMACODYNAMICS">12.2</a><span class="Italics">)</span><span class="Italics">]</span>. Studies using human liver preparations indicate that cytochrome P 450 3A4 (CYP 3A4) is the principal isoenzyme involved in the oxidation of exemestane. Exemestane is metabolized also by aldoketoreductases. </p>
<p><span class="Italics">Elimination:</span> Following administration of radiolabeled exemestane to healthy postmenopausal women, the cumulative amounts of radioactivity excreted in urine and feces were similar (42 Â± 3% in urine and 42 Â± 6% in feces over a 1-week collection period). The amount of drug excreted unchanged in urine was less than 1% of the dose.</p>
<p><span class="Bold Italics">Specific Populations</span><br><span class="Italics">Geriatric:</span> Healthy postmenopausal women aged 43 to 68 years were studied in the pharmacokinetic trials. Age-related alterations in exemestane pharmacokinetics were not seen over this age range.</p>
<p><span class="Italics">Gender:</span> The pharmacokinetics of exemestane following administration of a single, 25-mg tablet to fasted healthy males (mean age 32 years) were similar to the pharmacokinetics of exemestane in fasted healthy postmenopausal women (mean age 55 years).</p>
<p><span class="Italics">Race:</span> The influence of race on exemestane pharmacokinetics has not been evaluated.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</span> The pharmacokinetics of exemestane have been investigated in subjects with moderate or severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Childs-Pugh B or C). Following a single 25-mg oral dose, the AUC of exemestane was approximately 3 times higher than that observed in healthy volunteers.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span> The AUC of exemestane after a single 25-mg dose was approximately 3 times higher in subjects with moderate or severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> (creatinine clearance &lt;35 mL/min/1.73 m<span class="Sup">2</span>) compared with the AUC in healthy volunteers.</p>
<p><span class="Italics">Pediatric:</span> The pharmacokinetics of exemestane have not been studied in pediatric patients.</p>
<p><span class="Bold">Drug Interactions<br></span>Exemestane does not inhibit any of the major CYP isoenzymes, including CYP 1A2, 2C9, 2D6, 2E1, and 3A4.</p>
<p>In a <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> study of 10 healthy postmenopausal volunteers pretreated with potent CYP 3A4 inducer rifampicin 600 mg daily for 14 days followed by a single dose of exemestane 25 mg, the mean plasma C<span class="Sub">max</span> and AUC<span class="Sub"> 0â€“âˆž </span>of exemestane were decreased by 41% and 54%, respectively <span class="Italics">[see Dosage and Administration (</span><a href="#_f71b4a9f-934a-ac7a-3b93-41c935a5133b">2.2</a><span class="Italics">)</span><span class="Italics">and Drug Interactions (</span><a href="#DRUG_INTERACTIONS">7</a><span class="Italics">)]</span>. </p>
<p>In a clinical pharmacokinetic study, coadministration of ketoconazole, a potent inhibitor of CYP 3A4, has no significant effect on exemestane pharmacokinetics. Although no other formal drug-drug interaction studies with inhibitors have been conducted, significant effects on exemestane clearance by CYP isoenzyme inhibitors appear unlikely. <br></p>
<br><p><span class="Bold"></span></p>
<p></p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="NONCLINICAL_TOXICOLOGY"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="34083-6">
<a name="CARCINOGENESIS_AND_MUTAGENESIS_AND_IMPAIRMENT_OF_FERTILITY"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment Of Fertility</h2>
<p class="First">A 2-year carcinogenicity study in mice at doses of 50, 150, and 450 mg/kg/day exemestane (gavage), resulted in an increased incidence of <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatocellular adenomas</span> and/or carcinomas in both genders at the high dose level. Plasma AUC (<span class="Sub">0â€“24hr</span>) at the high dose were 2575 Â± 386 and 5667 Â± 1833 ng.hr/mL in males and females (approx. 34 and 75 fold the AUC in postmenopausal patients at the recommended clinical dose). An increased incidence of renal tubular <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> was observed in male mice at the high dose of 450 mg/kg/day. Since the doses tested in mice did not achieve an MTD, neoplastic findings in organs other than liver and kidneys remain unknown<span class="Bold">.</span></p>
<p>A separate carcinogenicity study was conducted in rats at the doses of 30, 100, and 315 mg/kg/day exemestane (gavage) for 92 weeks in males and 2 years in females. No evidence of carcinogenic activity up to the highest dose tested of 315 mg/kg/day was observed in females. The male rat study was inconclusive since it was terminated prematurely at Week 92. At the highest dose, plasma AUC <span class="Sub">(0â€“24hr)</span> levels in male (1418 Â± 287 ng.hr/mL) and female (2318 Â± 1067 ng.hr/mL) rats were 19 and 31 fold higher than those measured in postmenopausal cancer patients receiving the recommended clinical dose.</p>
<p>Exemestane was not mutagenic<span class="Italics"> in vitro</span> in bacteria (Ames test) or mammalian cells (V79 Chinese hamster lung cells). Exemestane was clastogenic in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> in vitro without metabolic activation but was not clastogenic <span class="Italics">in vivo</span> (micronucleus assay in mouse bone marrow). Exemestane did not increase unscheduled DNA synthesis in rat hepatocytes when tested<span class="Italics"> in vitro</span>. </p>
<p>In a pilot reproductive study in rats, male rats were treated with doses of 125â€“1000 mg/kg/day exemestane, beginning 63 days prior to and during cohabitation. Untreated female rats showed reduced fertility when mated to males treated with â‰¥500 mg/kg/day exemestane (â‰¥200 times the recommended human dose on a mg/m<span class="Sup">2</span> basis). In a separate study, exemestane was given to female rats at 4â€“100 mg/kg/day beginning 14 days prior to mating and through day 15 or 20 of gestation. Exemestane increased the placental weights at â‰¥4 mg/kg/day (â‰¥1.5 times the human dose on a mg/m<span class="Sup">2</span> basis). Exemestane showed no effects on ovarian function, mating behavior, and conception rate in rats given doses up to 20 mg/kg/day (approximately 8 times the recommended human dose on a mg/m<span class="Sup">2</span> basis); however, decreases in mean litter size and fetal body weight, along with delayed ossification were evidenced at â‰¥20 mg/kg/day. In general toxicology studies, changes in the ovary, including <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>, an increase in the incidence of <span class="product-label-link" type="condition" conceptid="193530" conceptname="Follicular cyst of ovary">ovarian cysts</span>, and a decrease in corpora lutea were observed with variable frequency in mice, rats, and dogs at doses that ranged from 3â€“20 times the human dose on a mg/m<span class="Sup">2</span> basis<span class="Bold">.</span>Â <span class="Bold"></span></p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="CLINICAL_STUDIES"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="42229-5">
<a name="_b4e768f6-f8d9-0a87-4c73-00301a07c199"></a><a name="section-13.1"></a><p></p>
<h2><span class="Bold">14.1 Adjuvant Treatment in Early Breast Cancer</span></h2>
<p class="First">The Intergroup Exemestane Study 031 (IES) was a randomized, double-blind, multicenter, multinational study comparing exemestane (25 mg/day) vs. tamoxifen (20 or 30 mg/day) in postmenopausal women with early breast cancer. Patients who remained disease-free after receiving adjuvant tamoxifen therapy for 2 to 3 years were randomized to receive an additional 3 or 2 years of exemestane or tamoxifen to complete a total of 5 years of hormonal therapy.Â </p>
<p>The primary objective of the study was to determine whether, in terms of disease-free survival, it was more effective to switch to exemestane rather than continuing tamoxifen therapy for the remainder of five years. Disease-free survival was defined as the time from randomization to time of local or distant recurrence of breast cancer, contralateral invasive breast cancer, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from any cause.</p>
<p>The secondary objectives were to compare the two regimens in terms of overall survival and long-term tolerability. Time to contralateral invasive breast cancer and distant recurrence-free survival were also evaluated.</p>
<p>A total of 4724 patients in the intent-to-treat (ITT) analysis were randomized to exemestane (Exemestane Tablets) 25 mg once daily (N = 2352) or to continue to receive tamoxifen once daily at the same dose received before randomization (N = 2372). Demographics and baseline tumor characteristics are presented in Table 5. Prior breast cancer therapy is summarized in Table 6.Â </p>
<p><img alt="table-5" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=61d86c55-9946-273f-4f22-42d3fc33d143&amp;name=table-5.jpg"></p>
<p><span class="Bold Underline"></span></p>
<p><img alt="table-6" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=61d86c55-9946-273f-4f22-42d3fc33d143&amp;name=table-6.jpg">Â </p>
<p>After a median duration of therapy of 27 months and with a median follow-up of 34.5 months, 520 events were reported, 213 in the exemestane group and 307 in the tamoxifen group (Table 7).</p>
<p><img alt="table-7" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=61d86c55-9946-273f-4f22-42d3fc33d143&amp;name=table-7.jpg"></p>
<p>Disease-free survival in the intent-to-treat population was statistically significantly improved [Hazard Ratio (HR) = 0.69, 95% CI: 0.58, 0.82, P = 0.00003, Table 8, Figure 1] in the exemestane arm compared to the tamoxifen arm. In the hormone receptor-positive subpopulation representing about 85% of the trial patients, disease-free survival was also statistically significantly improved (HR = 0.65, 95% CI: 0.53, 0.79, P = 0.00001) in the exemestane arm compared to the tamoxifen arm. Consistent results were observed in the subgroups of patients with node negative or positive disease, and patients who had or had not received prior chemotherapy. Overall survival was not significantly different in the two groups, with 116 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> occurring in the exemestane group and 137 in the tamoxifen group.</p>
<p></p>
<p><img alt="table-8" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=61d86c55-9946-273f-4f22-42d3fc33d143&amp;name=table-8.jpg"></p>
<p><img alt="figure-1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=61d86c55-9946-273f-4f22-42d3fc33d143&amp;name=figure-1.jpg"></p>
<p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_5c4255fa-9914-aff3-b48c-ca771445b823"></a><a name="section-13.2"></a><p></p>
<h2>
<span class="Bold">1</span><span class="Bold">4.2 Treatment of Advanced Breast Cancer</span>
</h2>
<p class="First">Exemestane 25 mg administered once daily was evaluated in a randomized double-blind, multicenter, multinational comparative study and in two multicenter single-arm studies of postmenopausal women with advanced breast cancer who had disease progression after treatment with tamoxifen for <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">metastatic disease</span> or as adjuvant therapy. Some patients also have received prior cytotoxic therapy, either as adjuvant treatment or for <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">metastatic disease</span>.</p>
<p>The primary purpose of the three studies was evaluation of objective response rate (complete response [CR] and partial response [PR]). Time to <span class="product-label-link" type="condition" conceptid="4168352" conceptname="Tumor progression">tumor progression</span> and overall survival were also assessed in the comparative trial. Response rates were assessed based on World Health Organization (WHO) criteria, and in the comparative study, were submitted to an external review committee that was blinded to patient treatment. In the comparative study, 769 patients were randomized to receive exemestane tablets 25 mg once daily (N = 366) or megestrol acetate 40 mg four times daily (N = 403). Demographics and baseline characteristics are presented in Table 9.</p>
<p><img alt="table-9" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=61d86c55-9946-273f-4f22-42d3fc33d143&amp;name=table-9.jpg"></p>
<p>The efficacy results from the comparative study are shown in Table 10. The objective response rates observed in the two treatment arms showed that exemestane tablets were not different from megestrol acetate. Response rates for exemestane tablets from the two single-arm trials were 23.4% and 28.1%.</p>
<p><img alt="table-10" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=61d86c55-9946-273f-4f22-42d3fc33d143&amp;name=table-10.jpg"></p>
<p>There were too few <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> occurring across treatment groups to draw conclusions on overall survival differences. The Kaplan-Meier curve for time to <span class="product-label-link" type="condition" conceptid="4168352" conceptname="Tumor progression">tumor progression</span> in the comparative study is shown in Figure 2.</p>
<p><img alt="figure-2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=61d86c55-9946-273f-4f22-42d3fc33d143&amp;name=figure-2.jpg"></p>
<p></p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="HOW_SUPPLIED"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Exemestane Tablets are white to off-white, round compound cup tablet with â€œ25â€? on one side and plain on the reverse. Exemestane tablets are packaged in HDPE bottles with a child-resistant screw cap, supplied in packs of 30 tablets.</p>
<p>30 tablet HDPE bottles Â Â Â Â Â Â Â Â Â Â Â Â Â Â NDC 47781-108-30</p>
<p>Store at 25Â°C (77Â°F); excursions permitted to 15Â°â€“30Â°C (59Â°â€“86Â°F) [see USP Controlled Room Temperature].</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="INFORMATION_FOR_PATIENTS"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Italics">See FDA-Approved Patient Labeling</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="_e26e63a9-bd27-610b-200d-fc86b0d48e88"></a><a name="section-15.1"></a><p></p>
<h2><span class="Bold">17.1 Premenopausal Women</span></h2>
<p class="First">Patients should be advised that exemestane is not for use in premenopausal women.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_f5ef193d-6aa8-1034-0283-7dfc36168795"></a><a name="section-15.2"></a><p></p>
<h2>
<span class="Bold">1</span><span class="Bold">7.2 Other Estrogen-Containing Agents</span>
</h2>
<p class="First">Patients should be informed that they should not take estrogen-containing agents while they are taking exemestane as these could interfere with its pharmacologic action.Â </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_ce923556-2394-6764-6960-3b2f492575da"></a><a name="section-15.3"></a><p></p>
<h2><span class="Bold">17.3 Bone Effects</span></h2>
<p class="First">Patients should be informed that exemestane lowers the level of estrogen in the body. This may lead to reduction in bone mineral density (BMD) over time. The lower the BMD, the greater the risk of <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> and <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_180572b5-f783-8432-0031-18ff9c52e971"></a><a name="section-16"></a><p></p>
<h1></h1>
<p class="First">Rx onlyÂ </p>
<p>Manufactured By:<br>Eirgen Pharma Ltd.<br>Waterford, Ireland</p>
<p>Distributed by:<br>Alvogen, Inc.<br>Pine Brook, NJ 07058 USA</p>
<p>PI108-00<br>Rev. 05/2014</p>
<br>
</div>
<div class="Section" data-sectionCode="68498-5">
<a name="_5927d051-4c85-a0bf-3bea-d71237cd939f"></a><a name="section-17"></a><p></p>
<h1><span class="Bold"></span></h1>
<p class="First"><span class="Bold">FDA-Approved Patient Labeling</span></p>
<p><span class="Bold"></span></p>
<p><span class="Bold Underline">Patient Information</span><br><span class="Bold">Exemestane Tablets</span><br><span class="Bold">(ek</span>â€³<span class="Bold">s</span><span class="Bold">Ä•</span><span class="Bold">-mesÂ´t</span><span class="Bold">Ä?</span><span class="Bold">n)</span></p>
<p>Read the patient information leaflet that comes with Exemestane Tablets before you start taking it. Read the leaflet each time you get a refill. There may be new information. This leaflet does not replace talking with your doctor about your condition or treatment. If you have any questions about Exemestane Tablets, ask your nurse, doctor, or pharmacist.</p>
<p><span class="Bold Underline">What are Exemestane Tablets?</span><br>Exemestane Tablets are used in women who are past <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>. It is used in:<span class="Bold Underline"></span><br>â€¢ <span class="Bold Underline">Early breast cancer</span> (cancer that has <span class="Italics">not </span>spread outside the breast). Exemestane Tablets lowers the risk the cancer will come back. It is for women who:<br>â€¢ <span class="Italics"></span>Have cancer that needs the female hormone estrogen to grow <span class="Italics">and<br>â€¢ </span>Had surgery for breast cancer, and possibly other treatments for breast cancer including radiation or chemotherapy <span class="Italics">and<br></span>â€¢ Have taken tamoxifen for 2 to 3 years <span class="Italics">and<br></span>â€¢ Are switching to Exemestane Tablets to finish 5 years in a row of hormonal therapy.<br>â€¢ <span class="Bold Underline">Advanced breast cancer</span> (cancer that has spread), to treat cancer that came back after treatment with tamoxifen. Certain breast cancers need the female hormone estrogen to grow (estrogen receptor-positive cancer). While you are taking Exemestane Tablets, your body stops making estrogen. Exemestane Tablets may slow or stop the growth of the cancer. Exemestane Tablets is hormone therapy. It is not chemotherapy. It is not hormone replacement therapy (HRT).</p>
<p><span class="Bold">Who should not take Exemestane Tablets?<br></span>Do not take Exemestane Tablets if:<br>â€¢ You are allergic to Exemestane Tablets or anything in it. The active ingredient is exemestane. There is a list of what is in Exemestane Tablets at the end of this leaflet.</p>
<p><span class="Bold Underline">What should I tell my doctor</span><span class="Bold Underline"></span><span class="Bold Underline">before taking Exemestane Tablets?</span></p>
<p><span class="Bold">Tell your doctor about all your medical conditions.<br></span><span class="Bold Underline"></span>Be sure to tell your doctor if you:<br>â€¢ Are still having menstrual periods (are not past <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>). Exemestane Tablets is only for women who are past <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>.<br>â€¢ Are pregnant or could be pregnant. Taking Exemestane Tablets during pregnancy may cause <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> or <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">miscarriage</span>.<br>â€¢ Are breast-feeding. Do not breast-feed while you are being treated with Exemestane Tablets.<br>â€¢ Have liver or kidney problems.</p>
<p><span class="Bold">Tell your doctor about all the medicines you take.</span><br>Include prescription and nonprescription medicines, herbal remedies, and vitamins. Exemestane Tablets and other medicines may affect how each other work.<br>Be sure to tell your doctor if you take:<br>â€¢ Medicines with estrogen, such as Premarin<span class="Sup">Â®</span>, other hormone replacement therapy, or birth control pills or patches. Exemestane Tablets should not be taken with these medicines as they could affect how well Exemestane Tablets work.<br>â€¢ Rifadin<span class="Sup">Â®</span> (rifampin)<br>â€¢ Dilantin<span class="Sup">Â®</span> (phenytoin), Tegretol<span class="Sup">Â®</span> (carbamazepine), or Luminal<span class="Sup">Â®</span> (phenobarbital)<br>â€¢ St. Johnâ€™s wort</p>
<p>Know what medicines you take. Keep a list of them with you. Show it to your doctor or pharmacist each time you get a new prescription.</p>
<p><span class="Bold Underline">What are possible side effects of Exemestane Tablets?</span></p>
<p><span class="Bold Italics">Serious Side Effects<br>â€¢ </span>Bone loss. Exemestane Tablets may reduce your bone mineral density (BMD) over time. This may raise your risk for bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>.<span class="Bold Underline"></span><br>â€¢ <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>. A small number of women had <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> or a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> while taking Exemestane Tablets.</p>
<p><span class="Bold Italics">Common Side Effects</span><br><span class="Bold">â€¢ </span><span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span> Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  <span class="Bold">â€¢ </span>feeling tired Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Â Â Â Â Â  <span class="Bold">â€¢ </span><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span><br><span class="Bold">â€¢ </span><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span><span class="Bold">Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  </span>Â  <span class="Bold">â€¢ </span>trouble sleepingÂ Â Â Â Â Â  Â Â Â Â Â Â Â Â  Â  Â <span class="Bold">â€¢ </span>increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span><br><span class="Bold">â€¢ </span><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â <span class="Bold">â€¢ </span>feeling anxious Â Â Â Â Â Â Â Â Â Â Â  Â Â Â  Â Â  <span class="Bold">â€¢ </span><span class="product-label-link" type="condition" conceptid="4012224" conceptname="Upset stomach">upset stomach</span><br><span class="Bold">â€¢ </span>difficulty in breathing <span class="Bold"></span></p>
<p>Your doctor may do blood tests to check your liver and kidney function during treatment.</p>
<p>These are not all the side effects with Exemestane Tablets. Ask your cancer nurse or doctor for a more complete list.</p>
<p><span class="Bold Underline">How should I take Exemestane Tablets?<br></span>â€¢ Take your dose of Exemestane Tablets once a day, every day, after a meal. Exemestane Tablets comes in 25 mg tablets you take by mouth. Your doctor will tell you how many Exemestane Tablets to take for your dose.<br>â€¢ Try to take your treatment at the same time each day.<br>â€¢ Take your medicine for as long as your doctor tells you.<br>â€¢ Tell your doctor if you do not feel well after starting Exemestane Tablets.<br>â€¢ If you miss a dose of Exemestane Tablets, take it as soon as you remember. If it is close to your next dose, just take your next dose at your regular time.<br>â€¢ Donâ€™t take more than one dose of Exemestane Tablets at a time.<br>â€¢ Make a note of when your prescription will run out. That way, you can get it refilled on time.</p>
<p><span class="Bold Underline">How do I store Exemestane Tablets?<br></span>â€¢ Keep Exemestane Tablets and all medicines out of the reach of children.<br>â€¢ Store Exemestane Tablets at room temperature, 77Â° F (25Â°C), in its original container.</p>
<p><span class="Bold Underline">General information about Exemestane Tablets<br></span>Doctors can prescribe medicines for conditions that are not in the patient information leaflet. Use Exemestane Tablets only for what your doctor prescribed. Do not give it to other people, even if they have the same conditions you have. It may harm them.</p>
<p>This leaflet gives the most important information about Exemestane Tablets. For more information about Exemestane Tablets, talk with your doctor, nurse, or pharmacist. You can call Alvogen at 1-866-770-3024.</p>
<p><span class="Bold Underline">What is in Exemestane Tablets?</span><span class="Bold"><br></span><span class="Bold">Active ingredient: </span>exemestane<br><span class="Bold">Inactive ingredients: </span>mannitol, copovidone, crospovidone, silicified microcrystalline cellulose, sodium starch glycolate, magnesium stearate, titanium dioxide, polyethylene glycol 400, and hypromellose.</p>
<p></p>
<p><span class="Bold">Rx only<br></span><span class="Bold"></span><span class="Bold"></span>All trademarks are the property of their respective owners.<br></p>
<p>Manufactured By:<br>Eirgen Pharma Ltd.<br>Waterford, Ireland<br></p>
<p>Distributed by:<br>Alvogen, Inc.<br>Pine Brook, NJ 07058 USA</p>
<p>PL108-00</p>
<p>Rev. 05/2014</p>
<br><br><br>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="_df53b0df-65df-3c03-dced-fec3882716fa"></a><a name="section-18"></a><p></p>
<h1></h1>
<p class="First"><img alt="label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=61d86c55-9946-273f-4f22-42d3fc33d143&amp;name=label.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>EXEMESTANEÂ 		
					</strong><br><span class="contentTableReg">exemestane tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:47781-108</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>EXEMESTANE</strong> (EXEMESTANE) </td>
<td class="formItem">EXEMESTANE</td>
<td class="formItem">25Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>COPOVIDONE K25-31</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">25</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:47781-108-30</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA200898</td>
<td class="formItem">07/25/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Alvogen Inc. 
							(008057330)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Eirgen Pharma Ltd.</td>
<td class="formItem"></td>
<td class="formItem">989968644</td>
<td class="formItem">manufacture(47781-108), pack(47781-108), analysis(47781-108)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 7/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>45f05e2e-ec00-9fb8-78ea-9e91bad9d29d</div>
<div>Set id: 61d86c55-9946-273f-4f22-42d3fc33d143</div>
<div>Version: 1</div>
<div>Effective Time: 20140725</div>
</div>
</div>Â <div class="DistributorName">Alvogen Inc. </div></p>
</body></html>
